Aerovance

Recombinant protein (IL-4 and IL-13 receptor antagonist) to treat asthma

placeBerkeley, California, United States calendar_todayFounded 2004 language aerovance.com

Innovation

17 patent families (7 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace dormant. Cited 321 times.

YearFilings
20121
20131
20171
20191

Investor mix

11 investors on record; lead investors include ProQuest Investments, BB Biotech Ventures.

Investor typeCountShare
Venture capital436%
Private equity218%
Bank & private debt218%
Other / undisclosed327%
Coming soon